In vivo probe of central cholinergic systems
- PMID: 3183305
- DOI: 10.1093/geronj/43.6.m158
In vivo probe of central cholinergic systems
Abstract
Age-related cognitive impairments and dementia of Alzheimer type have been linked to alterations in the cholinergic system. In the present study, evoked potentials and neuropsychological testing were obtained in healthy subjects during neuropharmacological manipulations including: scopolamine (anticholinergic), scopolamine plus physostigmine (anticholinesterase), scopolamine plus methylphenidate (adrenergic), and placebo. Scopolamine prolonged P3 latency and reduced spectral power of long latency evoked potentials without significantly altering earlier components. Physostigmine partially reversed these effects, but methylphenidate did not. Motor speed was slowed by scopolamine, but not by scopolamine plus methylphenidate. Cholinergic systems appear to be involved in generation or modulation of the P3 potential, possibly secondary to the cholinergic role in selective attention. Similar techniques may be useful as in vivo probes of central cholinergic function and thus as research and diagnostic aids in aging and disease.
Similar articles
-
Central cholinergic systems and the P3 evoked potential.Int J Neurosci. 1987 Apr;33(3-4):199-205. doi: 10.3109/00207458708987404. Int J Neurosci. 1987. PMID: 3596949
-
Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine.Pharmacol Biochem Behav. 1978 Dec;9(6):833-6. doi: 10.1016/0091-3057(78)90364-7. Pharmacol Biochem Behav. 1978. PMID: 106402 No abstract available.
-
Cholinergic modulation of an opposed effect of d-amphetamine and methylphenidate on the rearing response.Psychopharmacologia. 1975 Aug 21;43(2):169-73. doi: 10.1007/BF00421020. Psychopharmacologia. 1975. PMID: 1187951
-
Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar;29(3):411-22. doi: 10.1016/j.pnpbp.2004.12.008. Prog Neuropsychopharmacol Biol Psychiatry. 2005. PMID: 15795050 Review.
-
Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications.Neuroscience. 1995 Nov;69(1):1-41. doi: 10.1016/0306-4522(95)00241-a. Neuroscience. 1995. PMID: 8637608 Review.
Cited by
-
Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.Psychopharmacology (Berl). 2013 Feb;225(4):903-21. doi: 10.1007/s00213-012-2872-0. Epub 2012 Oct 3. Psychopharmacology (Berl). 2013. PMID: 23052568 Clinical Trial.
-
Cholinergic modulation of sensory perception and plasticity.Neurosci Biobehav Rev. 2023 Sep;152:105323. doi: 10.1016/j.neubiorev.2023.105323. Epub 2023 Jul 17. Neurosci Biobehav Rev. 2023. PMID: 37467908 Free PMC article. Review.
-
Cognition enhancers in age-related cognitive decline.Drugs Aging. 1996 Apr;8(4):245-74. doi: 10.2165/00002512-199608040-00003. Drugs Aging. 1996. PMID: 8920174 Review.